Page 10 - SCBJ-201512
P. 10
South China Business Journal
Overview of 26th
JCCT Outcomes
Through sustained
engagement during the course of
this past year, the United States and China
have reached agreement in several areas of
key importance to U.S. farmers, innovators,
manufacturers, workers and consumers,
including in the following areas:
IPR Protection and Enforcement: U.S. - China
Agriculture
China agreed to a number of IPR-related and Food
Conference
commitments that will facilitate much
Competition Policy: The United States
needed improvements in a wide range of and China made meaningful progress in
China’s enforcement of its Anti-Monopoly
industries that rely on the ability to protect significant market open to U.S. agricultural Law (AML). China agreed that commercial
and other products. secrets obtained in the process of AML
and enforce their IPR in China. Building on enforcement are protected under the law,
Pharmaceutical and Medical Devices: and shall not generally be disclosed to
several prior commitments, China clarified The United States and China achieved other agencies. China also attached great
concrete outcomes on implementing importance to maintaining coherence in the
several ongoing and intended efforts to mutually agreed goals of eliminating drug rules related to IPR in the context of AML.
and medical device application backlogs China also clarified that in the process of
revise China’s trade secrets system and and improving the time it takes to make creating guidance in relation to IPR in the
these products available to Chinese context of antimonopoly law, it will solicit
provide more effective aspects of its civil patients. These steps include publishing comments from relevant parties, including
annual performance reports, further the public.
judicial system to deter and respond to expansion of clinical trial exemptions
for medical devices, enhancing pre- Technology Policy: China committed to
the misappropriation of trade secrets. In submission consultation opportunities for nondiscriminatory and transparent policies
medical device applicants, and ensuring for ICT information security, including
addition, in recognition of several recent relevant reform measures are published assurances that Chinese banks are free
transparently. China also agreed that to purchase ICT products regardless of
developments to address challenges faced imported medical devices will be treated the country of origin, affirmations that
the same as domestically produced encryption regulations are narrow in scope,
by online counterfeiting, China agreed medical devices. These outcomes on and agreement to notify the WTO of a
pharmaceuticals and medical devices pave concerning draft insurance “secure and
to participate in a government-industry the way for significant increases in U.S. controllable” regulation for review by WTO
exports in healthcare, a key sector for members.
dialogue to enhance the systems available future growth in China as its population
ages and its economy matures.
to address these challenges and to increase
information sharing and cooperation on
cross-border enforcement between our two
countries. The United States also secured
China’s commitment to a transparent and
expeditious process for developing
Geographical Indication-
related measures that
JCCT will help keep
this
Special
8
Overview of 26th
JCCT Outcomes
Through sustained
engagement during the course of
this past year, the United States and China
have reached agreement in several areas of
key importance to U.S. farmers, innovators,
manufacturers, workers and consumers,
including in the following areas:
IPR Protection and Enforcement: U.S. - China
Agriculture
China agreed to a number of IPR-related and Food
Conference
commitments that will facilitate much
Competition Policy: The United States
needed improvements in a wide range of and China made meaningful progress in
China’s enforcement of its Anti-Monopoly
industries that rely on the ability to protect significant market open to U.S. agricultural Law (AML). China agreed that commercial
and other products. secrets obtained in the process of AML
and enforce their IPR in China. Building on enforcement are protected under the law,
Pharmaceutical and Medical Devices: and shall not generally be disclosed to
several prior commitments, China clarified The United States and China achieved other agencies. China also attached great
concrete outcomes on implementing importance to maintaining coherence in the
several ongoing and intended efforts to mutually agreed goals of eliminating drug rules related to IPR in the context of AML.
and medical device application backlogs China also clarified that in the process of
revise China’s trade secrets system and and improving the time it takes to make creating guidance in relation to IPR in the
these products available to Chinese context of antimonopoly law, it will solicit
provide more effective aspects of its civil patients. These steps include publishing comments from relevant parties, including
annual performance reports, further the public.
judicial system to deter and respond to expansion of clinical trial exemptions
for medical devices, enhancing pre- Technology Policy: China committed to
the misappropriation of trade secrets. In submission consultation opportunities for nondiscriminatory and transparent policies
medical device applicants, and ensuring for ICT information security, including
addition, in recognition of several recent relevant reform measures are published assurances that Chinese banks are free
transparently. China also agreed that to purchase ICT products regardless of
developments to address challenges faced imported medical devices will be treated the country of origin, affirmations that
the same as domestically produced encryption regulations are narrow in scope,
by online counterfeiting, China agreed medical devices. These outcomes on and agreement to notify the WTO of a
pharmaceuticals and medical devices pave concerning draft insurance “secure and
to participate in a government-industry the way for significant increases in U.S. controllable” regulation for review by WTO
exports in healthcare, a key sector for members.
dialogue to enhance the systems available future growth in China as its population
ages and its economy matures.
to address these challenges and to increase
information sharing and cooperation on
cross-border enforcement between our two
countries. The United States also secured
China’s commitment to a transparent and
expeditious process for developing
Geographical Indication-
related measures that
JCCT will help keep
this
Special
8
